Cost-effectiveness analysis of herpes zoster vaccination in 50-to 85-year-old immunocompetent Belgian cohorts : a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine
Abstract: Background A new adjuvanted subunit vaccine (HZ/su), with higher vaccine efficacy than live-attenuated vaccine (ZVL), has been licensed in Europe since March 2018. Therefore, Belgian decision-makers might need to re-assess their recommendations for vaccination against herpes zoster (HZ). Methods We conducted a cost-effectiveness analysis, using a Markov decision tree, of vaccinating 50- to 85-year-old immunocompetent Belgian cohorts with no vaccination, HZ/su, ZVL, and ZVL with booster after 10 years. Due to the uncertainty in vaccine waning of HZ/su vaccine beyond 4 years, we used a... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Schlagwörter: | Economics / Pharmacology. Therapy / Human medicine |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26916157 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/10067/1864310151162165141 |